Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04894734 · ClinicalTrials.gov registry record · NA

Spinal Cord Stimulation (SCS) for Spinal Cord Injury (SCI)

A NA study of Spinal Cord Injury at T1-T12 Level and Traumatic Thoracic Spinal Cord Contusion, sponsored by Nandan Lad, M.D., Ph.D..

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT04894734: Recruiting NA study of Spinal Cord Injury at T1-T12 Level and Traumatic Thoracic Spinal Cord Contusion, sponsored by Nandan Lad, M.D., Ph.D..

NCT04894734 is a NA study of Spinal Cord Injury at T1-T12 Level and Traumatic Thoracic Spinal Cord Contusion that is actively recruiting participants, run by Nandan Lad, M.D., Ph.D.. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04894734, a NA study of Spinal Cord Injury at T1-T12 Level and Traumatic Thoracic Spinal Cord Contusion, is actively recruiting participants, sponsored by Nandan Lad, M.D., Ph.D..

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this feasibility study is to compare the impact of Spinal cord stimulation \[SCS\] for Spinal Cord Injury (SCI) pain and rehabilitation. SCS, also known as Epidural Electrical Stimulation (EES), will be utilized along with conventional medical management (CMM) or CMM alone. Participation in this research study is expected to last approximately 24 months. All subjects will be evaluated and proceed with implantation of two SCS devices- one tailored based on the individual's SCI for the treatment of neuropathic pain of trunk and limb and a second near the bottom of the spinal cord (conus region) to study the impact on motor, sensory, bowel/bladder outcomes. All patients will also continue receiving CMM, such as medications and physical therapy. Participating subjects will be allocated to one of two treatment groups: 1. Placebo arm: SCS OFF + CMM. Under the direction of the study physician, the patient may receive a variety of treatments, such as medications and various forms of rehabilitation. 2. Treatment arm: SCS ON + CMM. The study treatment Spinal Cord Stimulation \[SCS\]: the study physician will perform a trial procedure to see if the study procedure works for the patient and may implant a permanent device if it is successful. There is a temporary trial procedure, or a "test drive," which usually lasts 5-7 days. If this is successful, patients will discuss a more permanent implant. This study involves the concurrent placement of two SCS devices (one focused on pain and the second for rehabilitation). For three months, treatment group subjects will have the SCS turned on and will have rehabilitation as part of their CMM. Participants in the placebo arm will have their SCS remain off and will undergo CMM with rehabilitation therapy similar to the treatment group. Neither the subjects nor the treatment team will know which patients are in the treatment or placebo arm. At the end of three months, the study group will be revealed and the placebo gro

Primary Outcome

The MPI-SCI consists of twelve 7-point subscales in three sections: (1) pain impact, (2) responses by significant others, and (3) activity. Our primary outcome is the average score of the 4 pain subscales (household activities, activities away from home, social activities, and outdoor work) for pain and consequences of SCI. These 4 scales are commonly used to create a single general activity scale. To define the degree to which pain and other consequences of injury reduced participation in a spe

Interventions

  • DEVICE EES on
  • DEVICE EES off

Study Locations (1)

North Carolina

  • Duke University Health Systems - Durham

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-12-30
Est. Completion 2027-10-31
Phase NA
Nandan Lad, M.D., Ph.D.

1 total trials

What NCT04894734 shows while recruiting

NCT04894734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 6 conditions, with Spinal Cord Injury at T1-T12 Level appearing as the primary indexed condition, and to 2 interventions - of which EES on is the first listed.

NCT04894734 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT04894734 about?

NCT04894734 is a clinical study titled "Spinal Cord Stimulation (SCS) for Spinal Cord Injury (SCI)". The purpose of this feasibility study is to compare the impact of Spinal cord stimulation \[SCS\] for Spinal Cord Injury (SCI) pain and rehabilitation. SCS, also known as Epidural Electrical Stimulation (EES), will be utilized along with conventional medical management (CMM) or CMM alone. Participat...

What is the current status of trial NCT04894734?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-12-30. Estimated completion is 2027-10-31.

What conditions does trial NCT04894734 study?

This clinical trial studies the following conditions: Spinal Cord Injury at T1-T12 Level, Traumatic Thoracic Spinal Cord Contusion, Thoracic Spinal Cord Trauma, Traumatic Thoracic Spinal Cord Laceration, Post-Traumatic Thoracic Myelopathy.

What interventions are being tested in trial NCT04894734?

The interventions under investigation include: EES on (DEVICE), EES off (DEVICE).

Who is sponsoring clinical trial NCT04894734?

This trial is sponsored by Nandan Lad, M.D., Ph.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04894734 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT04894734's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04894734, the US trial registry maintained by the National Library of Medicine. NCT04894734 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.